Viridian Therapeutics Announces Positive REVEAL-2 Trial Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy VRDN?
Viridian Therapeutics announced positive topline data from the REVEAL-2 phase 3 clinical trial of elegrobart in patients with chronic thyroid eye disease, TED. Elegrobart is a subcutaneously delivered, half-life-extended monoclonal antibody targeting the insulin-like growth factor-1 receptor. REVEAL-2 evaluated two dosing regimens, every four weeks and every eight weeks, compared with placebo. Key Highlights: REVEAL-2 met its primary endpoint with a highly statistically significant treatment effect; Elegrobart Q4W and Q8W achieved 50% and 54% proptosis responder rates at week 24, respectively, versus 15% placebo, both highly statistically significant results; Elegrobart Q4W achieved a statistically significant 61% diplopia responder rate at week 24, versus 38% placebo ; Elegrobart was generally well tolerated in both dose groups, with a safety profile consistent with REVEAL-1 and low rates of hearing impairment; Elegrobart is the only subcutaneous program to demonstrate positive phase 3 data in both active and chronic TED pivotal clinical trials and has the potential to be the first autoinjector treatment for TED; BLA submission on track for Q1 2027
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRDN
Wall Street analysts forecast VRDN stock price to rise
17 Analyst Rating
17 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.610
Low
14.20
Averages
41.71
High
61.00
Current: 16.610
Low
14.20
Averages
41.71
High
61.00
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viridian Therapeutics Raises $350M Through Upsized Public Offerings
- Upsized Offerings: Viridian Therapeutics successfully priced concurrent public offerings totaling $350 million, including $225 million of 1.75% convertible senior notes due 2032, indicating strong market demand for its securities.
- Debt Repayment Strategy: The company plans to allocate approximately $334.7 million in net proceeds to repay outstanding debt under its agreement with Hercules Capital, which will enhance its financial stability and reduce risk exposure.
- Market Expansion Initiatives: Part of the funds will support market expansion studies for its thyroid eye disease franchise, aiming to increase market share and strengthen competitive positioning in this therapeutic area.
- Pipeline Advancement: Viridian intends to use the financing to advance earlier-stage pipeline programs, which not only diversifies its product offerings but also lays the groundwork for potential future revenue growth.
See More
Viridian Therapeutics Completes $225 Million Financing
- Upsized Financing: Viridian Therapeutics announced an upsized public offering of $225 million in convertible senior notes and common stock, with estimated net proceeds of approximately $334.7 million, significantly bolstering the company's financial position to support R&D and market expansion.
- Convertible Notes Details: The notes carry an interest rate of 1.75% and mature in 2032, with an initial conversion price of about $24.65 per share, representing a 45% conversion premium, providing attractive terms for investors while offering flexibility for future financing.
- Clear Use of Proceeds: Viridian intends to utilize the proceeds to repay outstanding debt with Hercules Capital, fund market expansion studies for its thyroid eye disease (TED) franchise, and advance its early pipeline, demonstrating a strategic focus on future growth opportunities.
- Strong Underwriter Lineup: With Jefferies, Leerink Partners, and Goldman Sachs as joint book-running managers, the offering enhances market confidence, indicating investor optimism about Viridian's prospects, which could drive the company's stock price higher.
See More
Viridian Therapeutics Reveals Pricing for Increased Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock, Targeting Total Gross Proceeds of $350 Million
Announcement of Public Offerings: Viridian Therapeutics has announced the pricing of its upsized concurrent public offerings.
Details of Offerings: The offerings include 1.75% convertible senior notes due in 2032 and common stock, with aggregate gross proceeds expected to be $350 million.
See More
Viridian Therapeutics Stock Soars 33.36% Amid Treatment Launch
- Stock Surge: Viridian Therapeutics saw its stock price soar by 33.36% on Tuesday, closing at $18.75 per share, as investor sentiment was buoyed by the upcoming commercialization of its eye disease treatment, indicating strong market anticipation for its product.
- Launch Preparedness: The company announced its readiness for the launch of veligrotug, having assembled a field team including sales personnel and engaged with physicians, payers, and key opinion leaders, demonstrating proactive efforts in market promotion.
- Positive Clinical Data: CEO Steve Mahoney stated that with positive topline data from REVEAL-1 and REVEAL-2, the treatment has the potential to be the simplest and most convenient option for thyroid eye disease, further boosting investor confidence.
- Financial Performance Boost: Despite a 30% year-over-year increase in net loss to $92 million in the first quarter, total revenues surged by 96% to $141 million, highlighting strong growth potential driven by product demand.
See More
Viridian's Therapy Shows Strong Results, Stock Surges
- Significant Efficacy: Viridian's Elegrobart therapy achieved a 50% proptosis response rate at 24 weeks in the REVEAL-2 Phase 3 study, significantly outperforming the 15% rate for placebo, indicating its substantial clinical relevance in treating thyroid eye disease.
- FDA Application Plans: Viridian is expected to file for FDA approval of Elegrobart in Q1 2027, which, if granted, could open new revenue streams for the company and further solidify its market position in ophthalmic treatments.
- Earnings Beat Expectations: Although Viridian's Q1 loss widened to $0.90 per share, it was still better than Wall Street's estimate of $1.08, demonstrating effective management in cost control and R&D investments, which bolstered investor confidence.
- Market Sentiment Shift: Following the positive clinical results for Elegrobart, investor sentiment on Stocktwits shifted to 'extremely bullish', with expectations for the stock to surpass $20 in the near term, reflecting strong market recognition and growth potential for the therapy.
See More
Kopp Family Office Reduces Stake in Viridian Therapeutics
- Stake Reduction Details: Kopp Family Office reduced its stake in Viridian Therapeutics by 117,878 shares in Q1 2026, with an estimated transaction value of $3.5 million, resulting in a decrease in the stake's representation from 3.4% to 0.7% of AUM, indicating a cautious outlook on the company's future performance.
- Financial Performance Analysis: Viridian reported a net loss of $343 million for 2025, up from $270 million the previous year, despite maintaining a strong cash position of approximately $875 million, highlighting increased spending pressures related to clinical trials and commercial preparations.
- Market Competition Dynamics: In March 2026, Viridian's elegrobart candidate met primary endpoints in Phase 3 trials but faced poor market reaction, with shares dropping over 30% on the report day, while Amgen's competing product Tepezza demonstrated superior efficacy, intensifying market competition.
- Investor Strategy Adjustments: Kopp's stake reduction does not imply a total loss of confidence in Viridian but reflects routine management of high-risk investments, particularly in light of strong competitors like Amgen, leading investors to prefer diversified exposure through healthcare ETFs.
See More
Viridian Therapeutics Raises $350M Through Upsized Public Offerings
- Upsized Offerings: Viridian Therapeutics successfully priced concurrent public offerings totaling $350 million, including $225 million of 1.75% convertible senior notes due 2032, indicating strong market demand for its securities.
- Debt Repayment Strategy: The company plans to allocate approximately $334.7 million in net proceeds to repay outstanding debt under its agreement with Hercules Capital, which will enhance its financial stability and reduce risk exposure.
- Market Expansion Initiatives: Part of the funds will support market expansion studies for its thyroid eye disease franchise, aiming to increase market share and strengthen competitive positioning in this therapeutic area.
- Pipeline Advancement: Viridian intends to use the financing to advance earlier-stage pipeline programs, which not only diversifies its product offerings but also lays the groundwork for potential future revenue growth.
See More
Viridian Therapeutics Completes $225 Million Financing
- Upsized Financing: Viridian Therapeutics announced an upsized public offering of $225 million in convertible senior notes and common stock, with estimated net proceeds of approximately $334.7 million, significantly bolstering the company's financial position to support R&D and market expansion.
- Convertible Notes Details: The notes carry an interest rate of 1.75% and mature in 2032, with an initial conversion price of about $24.65 per share, representing a 45% conversion premium, providing attractive terms for investors while offering flexibility for future financing.
- Clear Use of Proceeds: Viridian intends to utilize the proceeds to repay outstanding debt with Hercules Capital, fund market expansion studies for its thyroid eye disease (TED) franchise, and advance its early pipeline, demonstrating a strategic focus on future growth opportunities.
- Strong Underwriter Lineup: With Jefferies, Leerink Partners, and Goldman Sachs as joint book-running managers, the offering enhances market confidence, indicating investor optimism about Viridian's prospects, which could drive the company's stock price higher.
See More
Viridian Therapeutics Reveals Pricing for Increased Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock, Targeting Total Gross Proceeds of $350 Million
Announcement of Public Offerings: Viridian Therapeutics has announced the pricing of its upsized concurrent public offerings.
Details of Offerings: The offerings include 1.75% convertible senior notes due in 2032 and common stock, with aggregate gross proceeds expected to be $350 million.
See More
Viridian Therapeutics Stock Soars 33.36% Amid Treatment Launch
- Stock Surge: Viridian Therapeutics saw its stock price soar by 33.36% on Tuesday, closing at $18.75 per share, as investor sentiment was buoyed by the upcoming commercialization of its eye disease treatment, indicating strong market anticipation for its product.
- Launch Preparedness: The company announced its readiness for the launch of veligrotug, having assembled a field team including sales personnel and engaged with physicians, payers, and key opinion leaders, demonstrating proactive efforts in market promotion.
- Positive Clinical Data: CEO Steve Mahoney stated that with positive topline data from REVEAL-1 and REVEAL-2, the treatment has the potential to be the simplest and most convenient option for thyroid eye disease, further boosting investor confidence.
- Financial Performance Boost: Despite a 30% year-over-year increase in net loss to $92 million in the first quarter, total revenues surged by 96% to $141 million, highlighting strong growth potential driven by product demand.
See More
Viridian's Therapy Shows Strong Results, Stock Surges
- Significant Efficacy: Viridian's Elegrobart therapy achieved a 50% proptosis response rate at 24 weeks in the REVEAL-2 Phase 3 study, significantly outperforming the 15% rate for placebo, indicating its substantial clinical relevance in treating thyroid eye disease.
- FDA Application Plans: Viridian is expected to file for FDA approval of Elegrobart in Q1 2027, which, if granted, could open new revenue streams for the company and further solidify its market position in ophthalmic treatments.
- Earnings Beat Expectations: Although Viridian's Q1 loss widened to $0.90 per share, it was still better than Wall Street's estimate of $1.08, demonstrating effective management in cost control and R&D investments, which bolstered investor confidence.
- Market Sentiment Shift: Following the positive clinical results for Elegrobart, investor sentiment on Stocktwits shifted to 'extremely bullish', with expectations for the stock to surpass $20 in the near term, reflecting strong market recognition and growth potential for the therapy.
See More
Kopp Family Office Reduces Stake in Viridian Therapeutics
- Stake Reduction Details: Kopp Family Office reduced its stake in Viridian Therapeutics by 117,878 shares in Q1 2026, with an estimated transaction value of $3.5 million, resulting in a decrease in the stake's representation from 3.4% to 0.7% of AUM, indicating a cautious outlook on the company's future performance.
- Financial Performance Analysis: Viridian reported a net loss of $343 million for 2025, up from $270 million the previous year, despite maintaining a strong cash position of approximately $875 million, highlighting increased spending pressures related to clinical trials and commercial preparations.
- Market Competition Dynamics: In March 2026, Viridian's elegrobart candidate met primary endpoints in Phase 3 trials but faced poor market reaction, with shares dropping over 30% on the report day, while Amgen's competing product Tepezza demonstrated superior efficacy, intensifying market competition.
- Investor Strategy Adjustments: Kopp's stake reduction does not imply a total loss of confidence in Viridian but reflects routine management of high-risk investments, particularly in light of strong competitors like Amgen, leading investors to prefer diversified exposure through healthcare ETFs.
See More
